AlphAIAlphAI — Financial news for AI agents
SEC EDGARAUG 172 min read$RCKT

Shah Gaurav sold $10K of RCKT

Shah Gaurav (CEO) sold 2,837 shares of ROCKET PHARMACEUTICALS, INC. (RCKT) at $3.38 on 2026-08-13.

Original reporting
SEC EDGAR · Shah Gaurav
Published Aug 17, 2026, 9:52 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 17, 2026, 10:17 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefInsider activity
Primary signal
$RCKT
Neutral
low confidence
Mentioned
$RCKT
Relevance
3/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$RCKTNeutralLow
01

Why it matters

The CEO’s open-market sale reduces insider holdings and may slightly influence sentiment, but the disclosure lacks any accompanying operational or financial update.

02

Market read

A new insider-sale datapoint for RCKT, with limited trading implications absent other catalysts.

03

What to watch

Insider sales are common and frequently non-informational; traders should weigh this against any concurrent news (earnings, guidance, financing, clinical/regulatory updates) not present here.

Relevance 3/10Novelty 3/10Timing: filed after-hours on 2026-08-17, transaction dated 2026-08-13

Background

The article is a SEC Form 4 insider transaction disclosure for Rocket Pharmaceuticals, filed 2026-08-17.

Company-level read

Ticker impact

$RCKTNeutralLow confidence
Context

Rocket Pharmaceuticals CEO Shah Gaurav sold 2,837 shares in an open-market transaction at $3.3810/share, per a new Form 4 filing.

Expected impact

Likely limited near-term impact; any effect is sentiment-driven and typically fades unless paired with other news.

Evidence & confidence

The filing discloses transaction size, price, and post-sale holdings, but provides no new company performance, guidance, or regulatory/operational development.

Market effects

Sector

No clear sector read-through from a single small insider sale without accompanying company-specific developments.

Regional

None indicated.

Global

None indicated.

Counterpoint

What could challenge this read

The absence of a disclosed 10b5-1 plan could be interpreted as less systematic selling, but insider sales still often reflect diversification or personal liquidity needs.

Key entities

  • issuer
    Rocket Pharmaceuticals, Inc.

    Company whose CEO insider sale is disclosed on Form 4.

  • insider
    Shah Gaurav

    CEO reporting an open-market sale of 2,837 shares.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

RCKT insider trading history →

Related articles

OCT 8
$RCKTMed

Goldman Sachs Upgrades Rocket Pharmaceuticals (RCKT) to Neutral

Goldman Sachs upgraded Rocket Pharmaceuticals (RCKT) to Neutral, citing encouraging clinical updates on its gene therapy candidate RP-A501. The company remains unprofitable with no revenue, but its market cap of $284M reflects growth expectations. RCKT's GF Score is 35/100, showing mixed fundamentals. Insiders have sold shares, while some institutional investors hold positions.

gurufocus.com5 min
OCT 8
$RCKTHigh

Why is Rocket Pharmaceuticals stock up 3% today?

Rocket Pharmaceuticals (RCKT) rose 2.8% after Goldman Sachs upgraded it to Neutral with a $4.00 price target, citing positive clinical data for RP-A501. Other analysts maintained bullish ratings, while some lowered targets due to long timelines. The company secured a $150M credit facility. The move was company-specific, as broader markets were down.

investing.com2 min
OCT 8
$RCKTMedAI 8/10

Rocket Pharmaceuticals bags $150 million as it pushes pivotal Danon disease study

Rocket Pharmaceuticals secured up to $150 million in financing from Hercules Capital, including an initial $35 million. The funds will support a pivotal Phase 2 study for its gene therapy candidate RP-A501 for Danon disease and broader cardiovascular pipeline development. The company reported $283.7 million in cash as of June 30, 2026, and expects the financing to extend its cash runway.

indianpharmapost.com2 min